Antag Therapeutics ApS

https://www.antagtherapeutics.com

Antag Therapeutics is a biotech start-up developing peptide-based therapeutics for the treatment of dietary-related metabolic diseases. The company is a spinout from the University of Copenhagen and stems from the research groups of Professors Mette M. Rosenkilde and Jens J. Holst. *

	Start	2014-01-01 splitoff (date ca.)
	Predecessor	University of Copenhagen
	Industry	GIP antagonist
	Industry 2	drug development
	Person	Sparre-Ulrich, Alexander Hovard (Antag Therapeutics 201706 CEO + Co-Founder)
	Person 2	Drejer, Kirsten (Symphogen 2000–201608 Founding CEO since 201609 Executive Director)

	Region	København (Copenhagen)
	Country	Denmark
	Street	3B Blegdamsvej
	City	2200 Copenhagen N
	Tel	+45-21-456537
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Novo Holdings A/S. (6/26/17). "Press Release: Anti-obesity Start-up Antag Therapeutics ApS Raises 2.7 mEUR with Novo Seeds". Copenhagen.

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Antag Therapeutics ApS

[1] Novo Holdings A/S. (6/26/17). "Press Release: Anti-obesity Start-up Antag Therapeutics ApS Raises 2.7 mEUR with Novo Seeds". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)